Tracer
Voyager Therapeutics Halts ALS Gene Therapy Development Due to Off-Target Effects
SOD1 ALS gene therapy, Off-target effects, VY9323, siRNA payload, TRACER capsid, Preclinical data, Drug development delay
Voyager Therapeutics Secures $100M Upfront Payment in Expanded Gene Therapy Partnership with Novartis
Gene therapy, Novartis, Voyager Therapeutics, Huntington’s disease, Spinal muscular atrophy (SMA), TRACER capsid discovery platform, Biotechnology collaboration